Zebularine: a new drug for epigenetic therapy

被引：143

作者：

Yoo, CB

Cheng, JC

Jones, PA

机构：

[1] Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90089 USA

[2] Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, Los Angeles, CA 90089 USA

[3] Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Biol, Los Angeles, CA 90089 USA

来源：

BIOCHEMICAL SOCIETY TRANSACTIONS | 2004年 / 32卷

关键词：

DNA methylation inhibitor; epigenetic therapy; zebularine;

D O I：

10.1042/BST0320910

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Regulatory genes are often hypermethylated at their promoter 5' regions and silenced in cancer. Epigenetic therapy with DNA methylation inhibitors have been shown to result in the demethylation and reactivation of these genes. Zebularine is a recently discovered mechanism-based inhibitor of DNA methylation, and has received much attention for its potential in clinical use. Further studies exploring the effectiveness of zebularine in a variety of settings could allow the development of novel therapies for cancer.

引用

页码：910 / 912

页数：3

共 35 条

[1]

Belinsky SA, 2003, CANCER RES, V63, P7089

[2]

Bender CM, 1999, MOL CELL BIOL, V19, P6690

[3] Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].